Cerebrospinal fluid biomarker panel of synaptic dysfunction in Alzheimer's disease and other neurodegenerative disorders
Authors:
Open Access
- 14 October 2022
- journal article
- research article
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (5) , 1775-1784
Abstract
Introduction: Synaptic degeneration is a key part of the pathophysiology of neurodegenerative diseases, and biomarkers reflecting the pathological alterations are greatly needed.Method: Seventeen synaptic proteins were quantified in a pathology‐confirmed cerebrospinal fluid cohort of patients with Alzheimer's disease (AD; n = 63), frontotemporal lobar degeneration (FTLD; n = 53), and Lewy body spectrum of disorders (LBD; n = 21), as well as healthy controls (HC; n = 48).Results: Comparisons revealed four distinct patterns: markers decreased across all neurodegenerative conditions compared to HC (the neuronal pentraxins), markers increased across all neurodegenerative conditions (14‐3‐3 zeta/delta), markers selectively increased in AD compared to other neurodegenerative conditions (neurogranin and beta‐synuclein), and markers selectively decreased in LBD and FTLD compared to HC and AD (AP2B1 and syntaxin‐1B).Discussion: Several of the synaptic proteins may serve as biomarkers for synaptic dysfunction in AD, LBD, and FTLD. Additionally, differential patterns of synaptic protein alterations seem to be present across neurodegenerative diseases.Highlights: A panel of synaptic proteins were quantified in the cerebrospinal fluid using mass spectrometry. We compared Alzheimer's disease, frontotemporal degeneration, and Lewy body spectrum of disorders. Pathology was confirmed by autopsy or familial mutations. We discovered synaptic biomarkers for synaptic degeneration and cognitive decline. We found differential patterns of synaptic proteins across neurodegenerative diseases.Keywords
This publication has 51 references indexed in Scilit:
- Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer's Disease Neuroimaging Initiative (ADNI) CSFProteomics – Clinical Applications, 2015
- Pathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body diseaseBiochemical Pharmacology, 2014
- National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approachActa Neuropathologica, 2011
- Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNIActa Neuropathologica, 2011
- Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an updateActa Neuropathologica, 2009
- The cellular functions of clathrinCellular and Molecular Life Sciences, 2006
- Diagnosis and management of dementia with Lewy bodiesNeurology, 2005
- 14-3-3 proteins and zeta isoform containing neurofibrillary tangles in patients with Alzheimer?s diseaseActa Neuropathologica, 2004
- Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease.Proceedings of the National Academy of Sciences, 1993
- Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairmentAnnals of Neurology, 1991